NYR: Cholesterol-Lowering Program Update

NYRADA INC.

• Nyrada's cholesterol-lowering drug candidate displayed an adverse signal in a final toxicology study, preventing it from undergoing clinical evaluation.
• The planned Phase I/IIa clinical trial has been deferred due to the unfavorable findings in the 28-day in vivo GLP toxicology study.
• Nyrada remains committed to developing an oral small molecule PCSK9 inhibitor drug as an approach to lowering high cholesterol.

2023-06-26 09:55:00

NYR: Brain Injury Program Preclinical Development Update

NYRADA INC.

• New brain injury drug candidate NYR-BI03 advanced due to superior potency and safety profile, replacing NYR-BI02.
• NYR-BI03 to be evaluated in WRAIR TBI efficacy study and stroke model study in 2H CY2023.
• Funding secured for preclinical development of NYR-BI03, preparing for a Phase I first-in-human study.

2023-06-09 08:18:00

NYR: Cholesterol-Lowering Program Preclinical Development Update

NYRADA INC.

• Preclinical dose formulation work and toxicology studies for Nyrada's Cholesterol-Lowering Program have been completed, with safety and pharmacology studies to be finalized by the end of April.
• Phase I/IIa first-in-human study is expected to start in early 2H CY2023.
• Nyrada has appointed Mr. Seth Gordon, formerly of Pfizer's Lipitor® marketing team, as Principal Consultant to advise on program strategy and asset development.

2023-04-11 08:28:00

NYR: Collaboration with Walter Reed and UNSW Extended to 2025

NYRADA INC.

1. Collaboration with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney (UNSW) has been extended from February 2023 through to January 2025 to evaluate the efficacy of Nyrada’s brain injury drug candidate to reduce secondary brain damage following a traumatic brain injury (TBI).
2. ~5.5 million people suffer a severe traumatic brain injury (TBI) each year, making TBI a serious and life-threatening condition with significant unmet clinical need.
3. The collaboration aligns with WRAIR's mission to develop ground-breaking solutions to mitigate the impact of TBIs which affect 1 in 25 US military service members.

2023-01-18 08:35:00

NYR: Brain Injury Program Update

NYRADA INC.

1. In vitro safety and toxicology studies commenced 2H CY2022 and are tracking well
2. No change to start of Phase I study, expected to commence in 1H CY2023, evaluating safety and tolerability of Nyrada’s brain injury drug in two indications, TBI and stroke
3. Progression of formulation work necessary for intravenous drug administration causes slight delay to preclinical stroke model study; results expected Q1 CY2023

2023-01-11 08:22:00